英特赛与阿科德签署协议收购Prothya生物解决方案公司-动脉网

Intas & Accord signs Agreement to acquire Prothya Biosolutions

CISION 等信源发布 2025-08-11 21:30



可切换为仅中文







AHMEDABAD,

艾哈迈达巴德，

India

印度

，

Aug. 11, 2025

2025年8月11日

/PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based primarily in

/PRNewswire/ -- Intas Pharmaceuticals的子公司Accord Plasma B.V.宣布已达成协议，将收购Prothya Biosolutions Belgium BV及其各子公司100%的股份，这是一家主要位于比利时的领先的血浆衍生医药产品（PDMP）企业。

the Netherlands

荷兰

and

和

Belgium

比利时

. Subject to the satisfaction of customary closing conditions, including regulatory clearances, the deal is anticipated to close shortly.

待满足包括监管许可在内的惯例交割条件后，该交易预计将在不久后完成。

This proposed acquisition marks a significant step in Intas and Accord's long-standing ambition to establish a global presence in the PDMP market, expanding Intas's established leadership in

此项拟议收购标志着 Intas 和 Accord 长期以来在 PDMP 市场建立全球影响力的雄心迈出了重要一步，进一步巩固了 Intas 的领导地位。

India

印度

into a truly international footprint.

成为一个真正的国际足迹。

Prothya Biosolutions, with primary operations in

普罗西亚生物解决方案公司，主要业务在

Amsterdam

阿姆斯特丹

and

和

Brussels

布鲁塞尔

and plasma collection centres across

和各地的血浆采集中心

Hungary

匈牙利

, employs approximately 1,200 people. The company is one of

，雇用大约1200人。该公司是其中之一

Europe's

欧洲的

largest plasma fractionators. Formed in 2021 through the integration of Plasma Industries Belgium, originally linked to the Belgian Red Cross, and Sanquin Plasma Products, formerly a part of the Sanquin Blood Supply Foundation, Prothya brings over 60 years of experience in plasma collection and the development of PDMPs..

最大的血浆分离公司。Prothya于2021年通过整合原本与比利时红十字会相关的Plasma Industries Belgium和原属Sanquin血液供应基金会的Sanquin Plasma Products成立，拥有超过60年的血浆采集和PDMPs开发经验。

Binish Chudgar

比尼什·楚德加尔

, Chairman of Intas & Accord, stated:

, Intas & Accord董事长表示：

'We are delighted to expand our plasma business through the acquisition of Prothya Biosolutions. Combined with our fractionation capabilities in

“我们很高兴通过收购Prothya Biosolutions来扩展我们的血浆业务。结合我们在分离技术方面的能力，

India

印度

, this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies.'

这使我们能够创建一个真正的全球血浆平台——为全球患者提供关键的、常常处方不足的治疗。

Intas's plasma division in

英特拉斯的血浆部门在

India

印度

has been supplying hospitals with PDMPs since 2015, supported by an annual fractionation capacity of over 1 million litres and exports to multiple international markets. Additional capacity is due to come online with the expansion of Intas's Gujarat-based facility.

自2015年以来，一直为医院提供PDMPs，年分馏能力超过100万升，并出口到多个国际市场。随着Intas位于古吉拉特邦的工厂扩建，额外产能即将上线。

Nir Epstein

尼尔·爱泼斯坦

, CEO of Prothya, commented:

Prothya公司首席执行官评论道：

'Over the past four years, we've expanded into new markets, advanced critical therapies, established our own plasma collection network in

“在过去的四年中，我们已经拓展了新市场，推进了关键疗法，并建立了自己的血浆采集网络。

Hungary

匈牙利

, and supplied plasma derivatives to some of the world's leading PDMP companies—all while building a stronger, more resilient organization. I want to thank our dedicated team for their unwavering commitment to our patients. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion.'.

，并为一些世界领先的PDMP公司提供血浆衍生物——同时建立一个更强大、更有韧性的组织。我要感谢我们敬业的团队对患者的坚定承诺。我相信Accord是支持Prothya及其员工下一阶段增长和全球扩张的正确选择。'

The global market for PDMPs—particularly IVIG (intravenous immunoglobulin)—is currently valued at

全球PDMPs市场，尤其是IVIG（静脉注射免疫球蛋白），目前估值为

$30 billion

300亿美元

and is expected to reach

预计将达到

$50 billion

500亿美元

by 2035. This acquisition will give Intas access to significant additional fractionation capacity, supported by Accord's commercial footprint spanning 85 countries.

到2035年。此次收购将使Intas获得显著的额外分馏能力，并得到Accord覆盖85个国家的商业网络的支持。

BofA Securities is acting as the exclusive financial advisor to Accord in this transaction.

美国银行证券公司在此交易中担任Accord的独家财务顾问。

Evercore is acting as the exclusive financial advisor to Prothya in this transaction.

在此次交易中，Evercore 担任 Prothya 的独家财务顾问。

About Intas

关于Intas

：

Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad,

Intas Pharmaceuticals Ltd.是一家领先的垂直整合制药公司，总部位于艾哈迈达巴德，

India

印度

, having end-to-end capabilities of formulation development, manufacturing, and marketing along with backward integration of APIs.

，具备从配方开发、生产到营销的端到端能力，同时实现原料药的后向整合。

Intas also has strong in-house biosimilar development and marketing capabilities, with more than 15 products being marketed. Intas is committed to expanding global healthcare access by providing affordable, high-quality medications through strategic partnerships and extensive R&D investment to meet the diverse needs of healthcare systems around the world.

Intas还拥有强大的内部生物类似药开发和营销能力，已有15多种产品上市。Intas致力于通过战略合作伙伴关系和广泛的研发投资，提供价格合理、高质量的药物，以满足全球医疗系统的多样化需求，从而扩大全球医疗的可及性。

Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare, to operate in global markets..

英特拉斯已建立了一个名为雅科德医疗的子公司网络，以在全球市场开展运营。

Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like

多年来，Intas通过自身发展和收购不断扩大其产品组合和业务范围。目前，它已遍布全球85多个国家，并在多个市场建立了强大的销售、营销和分销基础设施，如

North America

北美

，

Europe

欧洲

, Central &

，中部和

Latin America

拉丁美洲

，

Asia-Pacific